Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M(pro) Inhibitors

[Image: see text] The SARS-CoV-2 main protease (M(pro)) has been proven to be a highly effective target for therapeutic intervention, yet only one drug currently holds FDA approval status for this target. We were inspired by a series of publications emanating from the Jorgensen and Anderson groups d...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Leon, van der Westhuyzen, Aletta, Pribut, Nicole, Dentmon, Zackery W., Cui, Dan, D’Erasmo, Michael P., Bartsch, Perry W., Liu, Ken, Cox, Robert M., Greenlund, Sujay F., Plemper, Richard K., Mitchell, Deborah, Marlow, Joshua, Andrews, Meghan K., Krueger, Rebecca E., Sticher, Zachary M., Kolykhalov, Alexander A., Natchus, Michael G., Zhou, Bin, Pelly, Stephen C., Liotta, Dennis C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577883/
https://www.ncbi.nlm.nih.gov/pubmed/37849558
http://dx.doi.org/10.1021/acsmedchemlett.3c00335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577883/
https://www.ncbi.nlm.nih.gov/pubmed/37849558
http://dx.doi.org/10.1021/acsmedchemlett.3c00335

Ejemplares similares